The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea
Open Access
- 26 June 2018
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-8
Abstract
This study investigated the effects of diabetes and antidiabetic medications on the risk of pancreatic cancer(PaC). We extracted data on Koreans with newly diagnosed diabetes and selected age- and sex-matched controls provided by the National Health Insurance Corporation. Incident PaC was defined as a new registration in the Korea Central Cancer Registry under ICD-10 C25 with admission history until 2015. During 19,429,617.1 person-years, 8,589 PaCs were identified in 1,005,409 subjects for diabetes group and 4,021,636 subjects for control group. The diabetes group showed more than a two-fold risk for PaC compared with the control group. Among antidiabetic medications, metformin, thiazolidinedione, and dipeptidyl peptidase-4 inhibitor exposure was associated with decreased risk for future PaC(hazard ratio[95% confidence interval] = 0.86[0.77–0.96], 0.82[0.68–0.98], 0.57[0.51–0.64], respectively), whereas sulfonylurea and insulin exposure was related to increased risk(hazard ratio[95% CI] = 1.73[1.57–1.91], 2.86[1.43–5.74], respectively) compared to subjects with no drug exposure. Moreover, subjects with dual exposure history to metformin plus thiazolidinedione or metformin plus dipeptidyl peptidase-4 inhibitor had a lower risk of PaC compared to metformin-only treated subjects. In conclusion, Korean adults with diabetes are at higher risk of PaC compared with nondiabetic individuals, and this risk may be modified by antidiabetic medications.Keywords
Funding Information
- College of Medicine, Korea University (K1722341)
- National Research Foundation of Korea (2015R1A2A2A01003167, 2015R1C1A2A01052010)
This publication has 28 references indexed in Scilit:
- Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2014
- Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort studyDiabetes, Obesity and Metabolism, 2014
- Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control ConsortiumAnnals of Oncology, 2014
- The Impact of Perioperative Blood Glucose Levels on Pancreatic Cancer Prognosis and Surgical OutcomesPancreas, 2013
- A population-based cohort study in Taiwan––use of insulin sensitizers can decrease cancer risk in diabetic patients?Annals of Oncology, 2012
- Diabetes mellitus correlates with increased risk of pancreatic cancer: A population‐based cohort study in TaiwanJournal of Gastroenterology and Hepatology, 2011
- Risk of Malignant Neoplasm of the Pancreas in Relation to DiabetesDiabetes Care, 2011
- Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observationsDiabetologia, 2010
- Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanismsGut, 2004
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001